ESTRO 2025 - Abstract Book

S1921

Clinical - Urology

ESTRO 2025

Conclusion: SABR for high-risk prostate cancer is feasible and has acceptable acute and late side effects. However, further follow-up is required to confirm the results over a longer period of time.

Keywords: SABR, prostate cancer, elective nodal irradiation

References: 1.

Glicksman RM, Loblaw A, Morton G, Vesprini D, Szumacher E, Chung HT, et al. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT). International Journal of Radiation Oncology*Biology*Physics. 2024 May 1;119(1):100 – 9. 2. Foerster R, Zwahlen DR, Buchali A, Tang H, Schroeder C, Windisch P, et al. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. Cancers (Basel) [Internet]. 2021 Feb 1 [cited 2024 Nov 12];13(4):1 – 17. Available from: https://pubmed.ncbi.nlm.nih.gov/33673077/